Full Press Release Details
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to <12 Years with FOP
MIRM Positive Sentiment
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
Key Takeaway: Mirum Pharmaceuticals reported positive results from Cohort 2 of the PROGRESS study for ATEBRIOZ in pediatric patients aged 6 to under 12 with Fibrodysplasia Ossificans Progressiva. The data demonstrated a favorable clinical response in this rare disease population. These findings support the ongoing evaluation of zilurgisertib for treating this condition.
Market Sentiment Analysis
POSITIVE FACTORS
- Positive results reported from Cohort 2 of the study.
- ATEBRIOZ™ shows promise for pediatric patients.
- Study targets a rare condition, Fibrodysplasia Ossificans Progressiva.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+9%
120-day peak, hindsight
Typical move
5.2%
average across 15 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
Blinded CDCA
Phase 3 · CTX
Frequently Asked Questions
What is ATEBRIOZ™?
ATEBRIOZ™ (zilurgisertib) is a treatment for Fibrodysplasia Ossificans Progressiva.
What age group was studied in the PROGRESS trial?
The trial focused on pediatric patients aged 6 to under 12 years.
What condition does the PROGRESS study address?
The study addresses Fibrodysplasia Ossificans Progressiva (FOP).
What were the results of the PROGRESS study?
The study reported positive results from Cohort 2.